#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
Research is essential in developing and testing better treatments for mitochondrial disease. At Boston Children’s Hospital, this research is proceeding on several fronts.
We offer an experimental medication, dichloroacetate (DCA), to patients whose mitochondrial disease has caused lactic acidosis, a condition in which there is too much lactate in the blood and spinal fluid. DCA can lower lactate levels and potentially relieve a child’s symptoms. Boston Children’s is one of only a few institutions in the United States where the use of DCA is approved.
Boston Children’s is also participating in a Phase 3 multicenter trial of DCA for pyruvate dehydrogenase deficiency, a type of mitochondrial disorder in which buildup of lactate leads to neurologic problems.
In collaboration with Pankaj Agrawal, MD, from the Manton Center for Orphan Disease Research, we are seeking to identify novel (previously unknown) mutations that cause mitochondrial disease in humans.
In collaboration with the Harvard Stem Cell Institute and the Wyss Institute, Boston Children’s researchers are using induced pluripotent stem cells (iPS cells) from patients with Barth syndrome, a mitochondrial disorder affecting the heart, to create a “heart on a chip.” This model has provided new clues about how the mutation that causes Barth syndrome weakens heart muscle and potential ways to reverse the problem.
Pearson marrow pancreas syndrome is an extremely rare mitochondrial disorder that causes severe anemia by impairing development of blood-forming cells in the bone marrow. A team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center is using iPS cells from children with this disorder to create blood cells that can be studied in the lab. These cells may help them understand how the mutation in mitochondrial DNA occurs and causes disease, and may suggest ways to treat it.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”